Journal of Dementia

Enrico, J Dement 2023, 7:3

Review Article Open Access

A Review on the Deficits in Frontotemporal Dementia

Martina Enrico*

Department of Neurology, University College London, UK

Abstract

Deficits in neurotransmitters are still poorly understood in Frontotemporal Dementia (FTD). In prodromal MAPT disease, dopamine and serotonin pathways were found to be impaired, but no significant findings were found in prodromal GRN disease. This suggests that symptomatic treatment strategies could be tailored with a better understanding of neurotransmitter impairment, particularly in the prodromal stages of the disease. Dopamine, serotonin, glutamate, and acetylcholine pathways were found to be involved in all genetic subtypes of symptomatic FTD. The strength of GMV localization of dopamine and serotonin pathways was found to be correlated with social cognition scores, loss of empathy, and poor emotional cue response. This study, which assessed neurotransmitter deficits in monogenic FTD indirectly, provides novel insight into disease mechanisms and may suggest potential therapeutic targets to combat disease-related symptoms.

Keywords: Frontotemporal dementia; Frontotemporal lobar degeneration; Genes; Neurotransmitter

Introduction

Frontotemporal dementia (FTD) may be a neurodegenerative clutter characterized by dynamic behavioral, etymological, dysexecutive and engine unsettling influences. Its causes are hereditary in approximately a third of cases, with transformations in microtubule-associated protein tau (MAPT), progranulin (GRN) and chromosome 9 open perusing outline 72 (C9orf72) being the commonest causes [1]. Behavioral variation FTD (bvFTD) is the foremost common introduction, taken after by Essential Dynamic Aphasias (PPAs). Symptomatic MAPT change carriers appear a symmetrical brain decay including basically the anteromedial transient flaps, symptomatic GRN transformation carriers display a striking topsy-turvy design of cortical decay, while symptomatic C9orf72 change carriers show diffuse and symmetric cortical decay, including moreover back districts, thalamus and cerebellum [2]. Early neuroimaging modifications are portrayed around 5–10 a long time some time recently phenoconversion with a particular dispersion in each bunch. Regardless of the ceaseless headway of information on illness related components, little is realized about synapse processes that happen in FTD [3]. The involved neurotransmitter pathways may provide additional insight into disease pathogenesis. In addition, since each mutation group has distinct clinical and imaging characteristics, we could speculate that distinct neurotransmitter pathways are involved. As an outcome, research in this field could support distinguish custom-made restorative focuses for suggestive mediations [4].

Method

Although autopsy studies have demonstrated impairment of the dopaminergic, serotoninergic, GABAergic, and glutamatergic pathways, clinical trials have not reported significant benefits from neurotransmitter modulation on clinical symptoms in FTD. 2020). Small studies with unstratified populations and flaws in research methodology could be the cause of this disparity [5]. New tracers that are able to accurately measure the availability of specific receptors have been developed as a result of recent developments in positron emission tomography (PET) and single photon computed emission tomography (SPECT) tracer development. However, reliable results on in vivo neurotransmitter pathways in neurodegenerative disorders, particularly FTD, have been hampered by the requirement of large samples and the comparison of multiple tracers in the same subject [6]. In fact, FTD and FTD-related mutations have only a few small series studies or case reports. JuSpace performs a correlation between these alterations and each receptor/transporter map included in the toolbox, and it does so based on MRI measures derived by comparison between different groups [7]. JuSpace thusly can investigate in the event that the spatial examples of noticed cerebrum changes in the sickness of premium are connected with the dissemination of explicit synapses pathways, as gotten from autonomous sound worker populaces [8].

Result

The purpose of this study was to examine the relationship between clinical symptoms and changes in neurotransmitter pathways, particularly in prodromal FTD, the early stages of the disease [9]. We used the JuSpace tool to examine impairments in the dopamine, serotonin, glutamate, GABA, noradrenaline, and acetylcholine systems on a large sample of subjects from the international Genetic FTD Initiative (GENFI), taking into account individuals at various disease stages and with various pathogenetic mutations [10]. CAT12 possibly gives more powerful and exact exhibitions contrasted with other VBM pipelines. After the grey matter images had been normalized and modulated, they were smoothed using an 8 mm full width at half-maximum Gaussian kernel to reduce the likelihood of misalignment errors and increase the likelihood of detecting differences in small brain regions [11]. To determine whether the observed Fisher's z-transformed individual correlation coefficient distribution was significantly different from zero, exact permutation-based p-values were calculated using JuSpace's 10,000 permutations for randomly assigning group labels using orthogonal permutations [12]. Family Wise Error (FWE) was used to adjust for the number of tests in each analysis. Between the spatial distribution of the respective neurotransmitter maps and these z-transformed GMV maps, Spearman correlation coefficients (Fisher's

***Corresponding author:** Martina Enrico, Department of Neurology, University College London, UK, E-mail: martina.enr12@gmail.com

Received: 1-May-2023, Manuscript No: dementia-23-97236; **Editor assigned:** 4-May-2023; Pre QC No: dementia-23-97236 (PQ), **Reviewed:** 17-May-2023; QC No: dementia-23-97236; **Revised:** 24-May-2023; Manuscript No: dementia-23-97236 (R), **Published:** 30-May-2023, DOI: 10.4172/dementia.1000160

Citation: Enrico M (2023) A Review on the Deficits in Frontotemporal Dementia. J Dement 7: 160.

Z transformed) were calculated. To determine whether the observed correlation coefficients among patients deviate from a null distribution, exact permutation-based p-values, as implemented in JuSpace (10,000 permutations randomly assigning group labels using orthogonal permutations), were computed [13].

Discussion

Despite this, differences based on the causative gene and neurotransmitter impairment in monogenic FTD have not yet been evaluated. Individually or in combination, restoring these deficits has the potential to improve clinical and behavioral symptoms and contribute to a better understanding of the disease. In the current study, we investigated whether the localization of specific neurotransmitter pathways derived from independent healthy volunteer populations is connected to the spatial distribution of grey matter atrophy observed in various subtypes of monogenic prodromal and symptomatic FTD. JuSpace toolbox, which contrasts PET and SPECT-derived neurotransmitter maps with data from other imaging modalities like MRI. We looked at grey matter atrophy as an imaging sign of neurodegeneration in our study; however, other biomarkers may be even more sensitive, particularly in the prodromal phase. Grey matter changes in the prodromal stages of the disease were found to co-localize with a variety of neurotransmitter pathways, including dopamine and cholinergic systems in C9orf72 expansion carriers, dopamine and serotonin in MAPT mutation carriers, and GRN mutation carriers had no significant detectable changes. For sure, it has been accounted for that TDP-43 proteinopathy, the obsessive sign of C9orf72 extensions may cause dopamine changes and that C9orf72 expansion carriers have more severe memory impairments than carriers of MAPT and GRN mutations.

Conclusion

In contrast, in all monogenic FTD subtypes, symptomatic disease was associated with extensive involvement of various circuits and significant changes in dopaminergic, serotoninergic, and cholinergic pathways. In addition, we discovered additional involvement of the glutamatergic pathway in carriers of C9orf72 and GRN symptomatic mutations. It is important to note that monogenic FTD was spared by GABAergic and noradrenergic pathways. These discoveries affirm and broaden past writing information on examination concentrates as well as a new report on a huge gathering of PPA patients, yet additionally recommend an extra association of cholinergic framework in monogenic FTD which is missing in irregular illness. In fact, we were unable to confirm a co-localization of grey matter alteration and the GABAergic system, as opposed to previous research. Discoveries thus revealed contend for additional thinking about pharmacological control of explicit synapses, explicitly taking into account FTD subtypes and illness stage to check related side effects. In this perspective, investigating the involved neurotransmitter pathways may help identify biochemical alterations, which, in conjunction with clinical, biological, and neuroimaging biomarkers, may be useful in defining the various FTD subtypes in greater depth. Investigating neurotransmitter impairment may have an advantage over other biomarkers in terms of identifying individualized therapeutic targets to enhance symptomatic treatment.

References

1. Lotrich F, Pollock B (2005) Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 45: 1106–1122.
2. Patorno E, Bohn R, Wahl P, Avorn J, Patrick AR, et al. (2010) Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 303: 1401–1409.
3. Olesen JB, Hansen PR, Erdal J, Abildstrøm SZ, Weeke P, et al. (2010) Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidem Dr S 19: 518–524.
4. Leipzig R, Cumming R, Tinetti M (1999) Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 47: 30–39.
5. Gill S, Bronskill S, Normand S, Anderson GM, Sykora K, et al. (2007) Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146: 775–786.
6. Casey D, Haupt D, Newcomer J, Henderson DC, Sernyak MJ, et al. (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65(Suppl 7): 4–18.
7. Schneider LS, Dagerman KS, Insel P (2005) Risk of Death with Atypical Antipsychotic Drug Treatment for Dementia. JAMA 294: 1934–1943.
8. Meijer WEE, Heerdink ER, Nolen WA, Herings RMC, Leufkens HGM, et al. (2004) Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by Antidepressants. Arch Intern Med 164: 2367–2370.
9. Rasmussen K, Sampson S, Rummans T (2002) Electroconvulsive therapy and newer modalities for the treatment of medication-refractory mental illness. Mayo Clin Proc 77: 552–556.
10. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatr 23: 56–62.
11. Cohen R, Brunoni A, Boggio P, Fregni F (2010) Clinical predictors associated with duration of repetitive transcranial magnetic stimulation treatment for remission in bipolar depression: a naturalistic study. J Nerv Ment Dis 198: 679–681.
12. DigheDeo D, Shah A (1998) Electroconvulsive Therapy in Patients with Long Bone Fractures. J ECT 14: 115–119.
13. Takahashi S, Mizukami K, Yasuno F, Asada T (2009) Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics 9: 56–61.